Schizoaffective Disorder
📧 Sign up to get email alerts when something new happens for Schizoaffective Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Families With Substance Use and Psychosis: A Pilot Study [NA]
A completed pilot study from McLean Hospital investigating families with substance use and psychosis; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) [NA]
Completed clinical trial TIME studied targeted self-management for epilepsy and serious mental illness; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial [NA]
Completed randomized trial assessing the impact of physical activity on health outcomes in schizophrenia-spectrum disorders; results posted …
-
CLINICAL_TRIALS trial_result · 2022-09-06Clinical Trial Update: Cannabidiol Treatment in Patients With Early Psychosis [Phase 2]
Phase 2 trial of cannabidiol for early psychosis completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI) [NA]
A completed clinical trial on persistence-targeted smoking cessation in individuals with serious mental illness has posted results as of 202…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Stimulating the Brain to Improve Self-Awareness [NA]
A completed clinical trial on brain stimulation to improve self-awareness in schizophrenia and schizoaffective disorder, with results posted…
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: D-serine Augmentation of Neuroplasticity [Phase 1, Phase 2]
Phase 1/2 trial updates on D-serine augmentation to enhance neuroplasticity in schizophrenia and schizoaffective disorder; study completed w…
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: Research Into Antipsychotic Discontinuation and Reduction Trial [Phase 4]
Phase 4 trial updating research on discontinuation and reduction strategies for antipsychotics in schizophrenia-spectrum disorders.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. [Phase 2]
Phase 2 trial evaluating sodium benzoate and/or N-acetylcysteine added to treatment as usual in early schizophrenia spectrum disorders has c…
-
FDA approval · 2022-03-24FDA Approved: INVEGA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVEGA (paliperidone) from Janssen Pharmaceuticals, Inc. This action approves changes descri…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Telmisartan Pilot Study on Treatment Resistant Schizophrenia [Phase 2]
Phase 2 pilot study on telmisartan for treatment-resistant schizophrenia was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) [Phase 3]
Phase 3 trial evaluating efficacy and safety of asenapine using an active control in adults with schizophrenia or schizoaffective disorder; …
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Targeting Auditory Hallucinations With Alternating Current Stimulation [NA]
A completed clinical trial investigating alternating current stimulation for auditory hallucinations in schizophrenia/schizoaffective disord…
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Improving Accessibility and Personalization of CR for Schizophrenia [NA]
A completed clinical trial exploring accessibility and personalization of cognitive rehabilitation for schizophrenia and schizoaffective dis…
-
CLINICAL_TRIALS trial_result · 2022-01-12Clinical Trial Update: A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis [Phase 1, Phase 2]
A placebo-controlled study of IV ceftriaxone for refractory psychosis was terminated; results were posted in 2022.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Clozapine from Mylan Pharmaceuticals Inc., expanding its approved labeling and indications.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s Supplemental Application for CLOZAPINE, a generic version of clozapine under ANDA 202873. The approval…
-
FDA label_change · 2021-11-10FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
The FDA approved a supplemental application for VERSACLOZ (clozapine) submitted by TruPharma LLC.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves Mylan's supplemental application for Clozapine, allowing a generic version of Clozapine to be marketed.
-
FDA approval · 2021-11-01FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic quetiapine fumarate product from Aurobindo Pharma Limited, enabling its use as a g…
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: An Integrated Program for the Treatment of First Episode of Psychosis [NA]
Clinical trial update documenting completion of an integrated program for first-episode psychosis, with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-12Clinical Trial Update: Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY) [Phase 3]
Phase 3 clinical trial updating the burden of chronic psychotic disorders in Tanzania (CAPACITY) completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-08Clinical Trial Update: Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder [Phase 3]
Phase 3 clinical trial evaluating raloxifene augmentation in patients with schizophrenia-spectrum disorders has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Motivation and Skills Support (MASS) [NA]
Clinical trial update for the MASS study (K03404219) completed; results posted in 2021.
-
FDA approval · 2021-07-29FDA Approved: CLOZAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for clozapine from Accord Healthcare Inc. (generic clozapine). The approval pertains to a supplement…